Dr. Ho founded Drug Design Methodologies, which produced and licensed two highly successful commercial packages, RACHEL and CHARLIE, through Tripos, Inc. These products helped chemists refine weak binding leads into much more potent drugs. Over forty major pharmaceutical companies licensed these products until Tripos was sold to private investors in 2009. While at DDM, he maintained a senior scientist position in the Biochemistry Dept. at Washington University where he collaborated with numerous academic departments to develop ligands against specific targets. Dr. Ho has also served as a consultant to many pharmaceutical companies, including Monsanto, Pfizer and DuPont. Dr. Ho is a graduate of Purdue University and completed his MD/PhD from Washington University School of Medicine in St. Louis.

With her doctorate degree in Chemistry, Dr. Humblet spent her early day’s career in academia where she developed and applied computer-assisted molecular modeling techniques while building the foundation and blueprint for the software Sybyl, later commercialized by Tripos Inc. At the time, her research focused in the Pain, Neurosciences and Cardiovascular areas to elucidate structure-activity patterns for fentanyl, gabapentin, serotonin inhibitors among others. She transitioned to the Pharmaceutical Industry, initially as an individual contributor, and grew into an exceptional scientific and technical leader in preclinical discovery and enabling technologies. Her journey began at Parke-Davis in Ann Arbor, Michigan. It proceeded with appointments as a Director of Informatics at Abbott and a Senior Director of Computational Chemistry & Cheminformatics at Wyeth. Most recently, she led cheminformatics initiatives to transform drug discovery through artificial intelligence and machine learning techniques at Eli Lilly. Dr. Humblet has been published in more than 115 publications. She obtained her PhD from the University of Namur, Belgium.

Dr. Yeshokumar is a Medical Director in clinical research and development at Bristol Meyers Squibb, focused on neuroinflammation. She also holds an affiliate faculty position at the Icahn School of Medicine at Mount Sinai where she practices as an autoimmune neurologist. She cares for patients with autoimmune encephalitis, multiple sclerosis, neuromyelitis optica, neurosarcoidosis, and other autoimmune diseases that affect the central nervous system in children and adults. Her academic research focuses on understanding outcomes after autoimmune encephalitis and identifying clinical and biologic factors associated with these outcomes. Dr. Yeshokumar received her undergraduate degree from the Johns Hopkins University and her medical degree from Jefferson Medical College. She completed her pediatric neurology residency at Johns Hopkins Hospital and her multiple sclerosis and neuroimmune fellowship at the Children’s Hospital of Philadelphia and Hospital of the University of Pennsylvania.